Pa da evo zbilja ne znam vise sta napravit osim utuc u nekretninu lol
October 20, 2026 at 10:47 AM
Pa da evo zbilja ne znam vise sta napravit osim utuc u nekretninu lol
A long-term study in @uroweb.org shows endoscopic kidney-sparing surgery for UTUC achieves durable tumor control with renal preservation.
Although 5-year recurrence hit 49%, <25% ultimately required radical nephroureterectomy. 🩺
Read the article: https://bit.ly/3U9iwew
Although 5-year recurrence hit 49%, <25% ultimately required radical nephroureterectomy. 🩺
Read the article: https://bit.ly/3U9iwew
Study Explores Oncologic Outcomes After UTUC Kidney-Sparing Surgery
Investigators evaluated outcomes after endoscopic kidney-sparing surgery for upper tract urothelial carcinoma (UTUC).
bit.ly
October 21, 2026 at 12:27 AM
A long-term study in @uroweb.org shows endoscopic kidney-sparing surgery for UTUC achieves durable tumor control with renal preservation.
Although 5-year recurrence hit 49%, <25% ultimately required radical nephroureterectomy. 🩺
Read the article: https://bit.ly/3U9iwew
Although 5-year recurrence hit 49%, <25% ultimately required radical nephroureterectomy. 🩺
Read the article: https://bit.ly/3U9iwew
A urine methylation assay for #UrothelialCarcinoma demonstrated high sensitivity and specificity and showed higher sensitivity than urine cytology and fluorescence in situ hybridization.
ja.ma/3TOAkLC
ja.ma/3TOAkLC
October 11, 2026 at 12:30 PM
A urine methylation assay for #UrothelialCarcinoma demonstrated high sensitivity and specificity and showed higher sensitivity than urine cytology and fluorescence in situ hybridization.
ja.ma/3TOAkLC
ja.ma/3TOAkLC
A urine-based assay targeting AL021918.2 and vimentin methylation demonstrated 90.8% sensitivity and 93.2% specificity for #UrothelialCarcinoma detection according to a study published in @jamanetworkopen.com
Read the full article here: https://bit.ly/4hEjpop
Read the full article here: https://bit.ly/4hEjpop
Urine Methylation Assay Shows High Accuracy for Urothelial Carcinoma Detection
Various urine tests are showing promise for the diagnosis and surveillance of urothelial carcinoma, including bladder cancer and UTUC.
bit.ly
October 9, 2026 at 11:49 PM
A urine-based assay targeting AL021918.2 and vimentin methylation demonstrated 90.8% sensitivity and 93.2% specificity for #UrothelialCarcinoma detection according to a study published in @jamanetworkopen.com
Read the full article here: https://bit.ly/4hEjpop
Read the full article here: https://bit.ly/4hEjpop
ImPact Biotech has enrolled all 91 patients in its Phase 3 trial of padeliporfin VTP for upper-tract urothelial cancer. NDA filing expected in 2027.
ImPact Biotech completes ENLIGHTED Phase 3 for padeliporfin VTP
ImPact Biotech has treated all 91 patients in its Phase 3 LG-UTUC trial and expects to file an NDA with the FDA in 2027.
biotech.disruptsmedia.com
September 10, 2026 at 10:36 AM
ImPact Biotech has enrolled all 91 patients in its Phase 3 trial of padeliporfin VTP for upper-tract urothelial cancer. NDA filing expected in 2027.
#Nectin-4 is a key target for #ADCs in #urothelial carcinoma. This study evaluated Nectin-4 features in bladder #UC and #UTUC, revealing distinct expression patterns and associated immune contextures.
buff.ly/vFzQdrH
buff.ly/vFzQdrH
August 18, 2026 at 9:51 PM
#Nectin-4 is a key target for #ADCs in #urothelial carcinoma. This study evaluated Nectin-4 features in bladder #UC and #UTUC, revealing distinct expression patterns and associated immune contextures.
buff.ly/vFzQdrH
buff.ly/vFzQdrH
Day One of #BLADDR25 #GlobalForum25 in Portugal 🇵🇹
Kicking off with a presentation from Dr. Eva Comperat of Vienna, Austria🇦🇹 & Paris, France🇫🇷
Session: Moving down in the urinary system: UTUC
Presenting: Genomic/tumour characterisation
Kicking off with a presentation from Dr. Eva Comperat of Vienna, Austria🇦🇹 & Paris, France🇫🇷
Session: Moving down in the urinary system: UTUC
Presenting: Genomic/tumour characterisation
December 3, 2025 at 2:52 PM
Day One of #BLADDR25 #GlobalForum25 in Portugal 🇵🇹
Kicking off with a presentation from Dr. Eva Comperat of Vienna, Austria🇦🇹 & Paris, France🇫🇷
Session: Moving down in the urinary system: UTUC
Presenting: Genomic/tumour characterisation
Kicking off with a presentation from Dr. Eva Comperat of Vienna, Austria🇦🇹 & Paris, France🇫🇷
Session: Moving down in the urinary system: UTUC
Presenting: Genomic/tumour characterisation
Kidney-sparing management in low-grade UTUC: what does 5-year follow-up show?
Experts review long-term outcomes and case-based approaches to recurrence and surveillance.
▶️ Access the program today: bit.ly/4kcoJ1L
#UTUC #UroOncology #KidneySparing #Urology #ClinicalPractice
Experts review long-term outcomes and case-based approaches to recurrence and surveillance.
▶️ Access the program today: bit.ly/4kcoJ1L
#UTUC #UroOncology #KidneySparing #Urology #ClinicalPractice
February 3, 2026 at 2:00 PM
Kidney-sparing management in low-grade UTUC: what does 5-year follow-up show?
Experts review long-term outcomes and case-based approaches to recurrence and surveillance.
▶️ Access the program today: bit.ly/4kcoJ1L
#UTUC #UroOncology #KidneySparing #Urology #ClinicalPractice
Experts review long-term outcomes and case-based approaches to recurrence and surveillance.
▶️ Access the program today: bit.ly/4kcoJ1L
#UTUC #UroOncology #KidneySparing #Urology #ClinicalPractice
🧠 2.5D deep learning adds incremental prognostic value over 2D approaches
link.springer.com/article/10.1... (Xiang Peng et al.)
link.springer.com/article/10.1... (Xiang Peng et al.)
A perioperative multi-modal fusion and deep learning-based prognostic system for upper tract urothelial carcinoma: a multi-institutional study - Insights into Imaging
Objectives Precise perioperative risk stratification for upper tract urothelial carcinoma (UTUC) is essential. We developed a multimodal prognostic model integrating perioperative clinical data,…
link.springer.com
July 29, 2026 at 12:02 PM
🧠 2.5D deep learning adds incremental prognostic value over 2D approaches
link.springer.com/article/10.1... (Xiang Peng et al.)
link.springer.com/article/10.1... (Xiang Peng et al.)
Bolesno koliko su spremni utuc para u to a ne u place. Bas bolesno. Nama su srezali. Neki su vec spickali mesecnu alokaciju na nekim platformama
June 9, 2026 at 7:21 AM
Bolesno koliko su spremni utuc para u to a ne u place. Bas bolesno. Nama su srezali. Neki su vec spickali mesecnu alokaciju na nekim platformama
Bit ce posebna dretva o hajku danas, ali vraćam se u grad nakon 25 km u nogama i mislim si kako ću utuć neko omanje krme za ručak i osjetim miris roštilja. Uglavnom, evo me u nekom ćumezu podno Monte Pelegrina na rotoru podno bilboarda na beefetini
April 30, 2025 at 3:56 PM
Bit ce posebna dretva o hajku danas, ali vraćam se u grad nakon 25 km u nogama i mislim si kako ću utuć neko omanje krme za ručak i osjetim miris roštilja. Uglavnom, evo me u nekom ćumezu podno Monte Pelegrina na rotoru podno bilboarda na beefetini
Tu uvalu čine Grotta De Colombi s koje puca pogled na drugu stranu i the Rocky Skull. Tamo sam odlučio utuć energy bar, ali jedan galeb je skužio da je foodara u igri i cijelo vrijeme je pokusavao popalit ručak
April 26, 2024 at 8:28 AM
Tu uvalu čine Grotta De Colombi s koje puca pogled na drugu stranu i the Rocky Skull. Tamo sam odlučio utuć energy bar, ali jedan galeb je skužio da je foodara u igri i cijelo vrijeme je pokusavao popalit ručak
Looking forward to #ASCOGU25
#Prostate: Combos w/ iPARP- and Lu- , EZH2
#Urothelial: Updates, HER-2, FGFR3, and high-risk UTUC
#Renal: Updates, UO3B, KIM-1, HIF-2 inh and MET inh
#Testicular: RPLND advanced Seminoma
#Penile: IO-chemo for advanced Ca
@rickyfrazer1.bsky.social @jmcgrane.bsky.social
#Prostate: Combos w/ iPARP- and Lu- , EZH2
#Urothelial: Updates, HER-2, FGFR3, and high-risk UTUC
#Renal: Updates, UO3B, KIM-1, HIF-2 inh and MET inh
#Testicular: RPLND advanced Seminoma
#Penile: IO-chemo for advanced Ca
@rickyfrazer1.bsky.social @jmcgrane.bsky.social
February 10, 2025 at 12:46 AM
Looking forward to #ASCOGU25
#Prostate: Combos w/ iPARP- and Lu- , EZH2
#Urothelial: Updates, HER-2, FGFR3, and high-risk UTUC
#Renal: Updates, UO3B, KIM-1, HIF-2 inh and MET inh
#Testicular: RPLND advanced Seminoma
#Penile: IO-chemo for advanced Ca
@rickyfrazer1.bsky.social @jmcgrane.bsky.social
#Prostate: Combos w/ iPARP- and Lu- , EZH2
#Urothelial: Updates, HER-2, FGFR3, and high-risk UTUC
#Renal: Updates, UO3B, KIM-1, HIF-2 inh and MET inh
#Testicular: RPLND advanced Seminoma
#Penile: IO-chemo for advanced Ca
@rickyfrazer1.bsky.social @jmcgrane.bsky.social
i love the fire ending its the best one
June 13, 2026 at 4:54 AM
i love the fire ending its the best one
#BCG may be less effective in patients who develop metachronous #NMIBC after radical nephrouretectomy for #UTUC. Reported at #SUO25 by Yu Guang Tan, MBBS, of Singapore General Hospital covered by @renalurologynews.bsky.social.
https://bit.ly/4sJXtf5
#bladdercancer #blcsm
https://bit.ly/4sJXtf5
#bladdercancer #blcsm
January 14, 2026 at 5:47 PM
#BCG may be less effective in patients who develop metachronous #NMIBC after radical nephrouretectomy for #UTUC. Reported at #SUO25 by Yu Guang Tan, MBBS, of Singapore General Hospital covered by @renalurologynews.bsky.social.
https://bit.ly/4sJXtf5
#bladdercancer #blcsm
https://bit.ly/4sJXtf5
#bladdercancer #blcsm
I knew about it from friends, and it was the first place I went. What a disappointment!
And the Kidney Foundation has absolutely nothing about UTUC or Lynch.
This is a condition that really needs some visibility. It affects 1 in 300 people, which is 1,000,000 Americans.
And the Kidney Foundation has absolutely nothing about UTUC or Lynch.
This is a condition that really needs some visibility. It affects 1 in 300 people, which is 1,000,000 Americans.
May 23, 2026 at 12:48 PM
I knew about it from friends, and it was the first place I went. What a disappointment!
And the Kidney Foundation has absolutely nothing about UTUC or Lynch.
This is a condition that really needs some visibility. It affects 1 in 300 people, which is 1,000,000 Americans.
And the Kidney Foundation has absolutely nothing about UTUC or Lynch.
This is a condition that really needs some visibility. It affects 1 in 300 people, which is 1,000,000 Americans.
MOZU 전원 해고에 다시 재집결 끝에 담당 같은 것도 흐지부지 되었기 때문에 무엇을 하면 좋을지 모른다는 느낌 존나 쎄함 ㅋㅋ【ストグラ】MOZUボアが再度苦しい状況を吐き出し励ます男達【ヨシャパテ ラブストレート小里馬ァ 山田カイキ GTA5 】 www.youtube.com/watch?v=utUC...
【ストグラ】MOZUボアが再度苦しい状況を吐き出し励ます男達【ヨシャパテ ラブストレート小里馬ァ 山田カイキ GTA5 】
YouTube video by ヨシャパテ【ストグラ】公式切り抜きch
www.youtube.com
January 12, 2025 at 11:45 AM
MOZU 전원 해고에 다시 재집결 끝에 담당 같은 것도 흐지부지 되었기 때문에 무엇을 하면 좋을지 모른다는 느낌 존나 쎄함 ㅋㅋ【ストグラ】MOZUボアが再度苦しい状況を吐き出し励ます男達【ヨシャパテ ラブストレート小里馬ァ 山田カイキ GTA5 】 www.youtube.com/watch?v=utUC...
솔직히 그만두는 것 하나라도 불안이 따라다니기 때문에 문제 아니냐 ㅋㅋ【ストグラ】MOZUボアが再度苦しい状況を吐き出し励ます男達【ヨシャパテ ラブストレート小里馬ァ 山田カイキ GTA5 】 www.youtube.com/watch?v=utUC...
【ストグラ】MOZUボアが再度苦しい状況を吐き出し励ます男達【ヨシャパテ ラブストレート小里馬ァ 山田カイキ GTA5 】
YouTube video by ヨシャパテ【ストグラ】公式切り抜きch
www.youtube.com
January 12, 2025 at 11:45 AM
솔직히 그만두는 것 하나라도 불안이 따라다니기 때문에 문제 아니냐 ㅋㅋ【ストグラ】MOZUボアが再度苦しい状況を吐き出し励ます男達【ヨシャパテ ラブストレート小里馬ァ 山田カイキ GTA5 】 www.youtube.com/watch?v=utUC...
Ein Fortschritt in der Diagnostik von #Urothelkarzinomen im oberen Harntrakt (UTUC)? Die Kryobiopsie könnte ihn bringen. Einer Studie zufolge, liefert sie Proben, die weniger Artefakte aufweisen und diagnostisch überlegen sind. (kostenfrei nach Reg.) #medsky #Urologie
Kryobiopsie punktet bei UTUC-Diagnostik
Ein Fortschritt in der Diagnostik von Urothelkarzinomen im oberen Harntrakt (UTUC)? Die Kryobiopsie könnte ihn bringen. Einer Studie zufolge, liefert sie Proben, die weniger Artefakte aufweisen und diagnostisch überlegen sind.
www.springermedizin.de
October 2, 2025 at 4:50 AM
Ein Fortschritt in der Diagnostik von #Urothelkarzinomen im oberen Harntrakt (UTUC)? Die Kryobiopsie könnte ihn bringen. Einer Studie zufolge, liefert sie Proben, die weniger Artefakte aufweisen und diagnostisch überlegen sind. (kostenfrei nach Reg.) #medsky #Urologie
New guidance supports high-quality, consistent care for patients with upper urinary tract urothelial cancer (UTUC) – GIRFT
GIRFT Guidance to support NHS clinicians and service managers to deliver high-quality, consistent care for patients with upper urinary tract urothelial cancer (UTUC) is now…
GIRFT Guidance to support NHS clinicians and service managers to deliver high-quality, consistent care for patients with upper urinary tract urothelial cancer (UTUC) is now…
New guidance supports high-quality, consistent care for patients with upper urinary tract urothelial cancer (UTUC) – GIRFT
GIRFT Guidance to support NHS clinicians and service managers to deliver high-quality, consistent care for patients with upper urinary tract urothelial cancer (UTUC) is now available on the GIRFT website. Developed by a GIRFT expert working group, in collaboration with the British Association of Urological Surgeons (BAUS) and the British Association of Urological Nursing (BAUN), the new guide aims to address known variations in diagnostic practices, significant delays to treatment and potentially suboptimal outcomes.
trfthealthweeklydigest.wordpress.com
June 23, 2026 at 6:57 AM
New guidance supports high-quality, consistent care for patients with upper urinary tract urothelial cancer (UTUC) – GIRFT
GIRFT Guidance to support NHS clinicians and service managers to deliver high-quality, consistent care for patients with upper urinary tract urothelial cancer (UTUC) is now…
GIRFT Guidance to support NHS clinicians and service managers to deliver high-quality, consistent care for patients with upper urinary tract urothelial cancer (UTUC) is now…
A single dose of intravesical pirarubicin within 24 hours of RNU improved relapse-free survival over 3 years in patients with UTUC, and helped to prevent bladder recurrence.
https://www.renalandurologynews.com/news/utuc-urothelial-carcinoma-intravesical-pirarubicin-prolong-surgery-treatment/
https://www.renalandurologynews.com/news/utuc-urothelial-carcinoma-intravesical-pirarubicin-prolong-surgery-treatment/
Intravesical Pirarubicin After UTUC Surgery May Prolong Relapse-Free Survival
After showing early promise, a phase 3 trial tested intravesical pirarubicin after radical nephroureterectomy for upper tract urothelial carcinoma (UTUC).
www.renalandurologynews.com
August 3, 2026 at 3:29 PM
A single dose of intravesical pirarubicin within 24 hours of RNU improved relapse-free survival over 3 years in patients with UTUC, and helped to prevent bladder recurrence.
https://www.renalandurologynews.com/news/utuc-urothelial-carcinoma-intravesical-pirarubicin-prolong-surgery-treatment/
https://www.renalandurologynews.com/news/utuc-urothelial-carcinoma-intravesical-pirarubicin-prolong-surgery-treatment/
Patients with UTUC and stone history are at high risk for poor survival outcomes and should be offered adjuvant therapy.
www.renalandurologynews.com/news/surviva... #kidneystones
www.renalandurologynews.com/news/surviva... #kidneystones
Survival Outcomes Worse in UTUC With Stone History
Patients with upper tract urothelial carcinoma (UTUC) and urinary tract stone history are a high-risk subgroup requiring greater surveillance.
www.renalandurologynews.com
November 21, 2025 at 3:13 PM
Patients with UTUC and stone history are at high risk for poor survival outcomes and should be offered adjuvant therapy.
www.renalandurologynews.com/news/surviva... #kidneystones
www.renalandurologynews.com/news/surviva... #kidneystones
Long-term data from a prospective phase 2 trial show neoadjuvant cisplatin-based chemotherapy before nephroureterectomy provides durable survival benefits in high-risk, nonmetastatic UTUC.
www.renalandurologynews.com/news/urothel... #bladdercancer
www.renalandurologynews.com/news/urothel... #bladdercancer
Neoadjuvant Chemo Improves Long-Term Survival Outcomes in High-Risk UTUC
Long-term trial findings support use of neoadjuvant chemotherapy in patients with high-risk localized upper tract urothelial carcinoma (UTUC).
www.renalandurologynews.com
October 8, 2025 at 1:29 PM
Long-term data from a prospective phase 2 trial show neoadjuvant cisplatin-based chemotherapy before nephroureterectomy provides durable survival benefits in high-risk, nonmetastatic UTUC.
www.renalandurologynews.com/news/urothel... #bladdercancer
www.renalandurologynews.com/news/urothel... #bladdercancer